CytoMed Therapeutics Ltd Stock Price, News & Analysis

CytoMed Therapeutics (NASDAQ: GDTC) secured a non-dilutive investment into its subsidiary LongevityBank from ICH Capital, with ICH Capital agreeing to invest up to US$500,000 for a 10.0% post-money stake in LongevityBank.

CytoMed will concentrate on donor-derived allogeneic cell therapies (IND Phase I ongoing in Singapore; Phase II IIT in India), while LongevityBank will focus on autologous cell banking and therapies. CytoMed said CNIPA granted patents for its gamma delta and CAR-γδ technologies, and cited China State Council Decree No. 818 (Oct 10, 2025) as a new regulatory pathway to clinical application for cell therapies.

CytoMed Therapeutics (NASDAQ: GDTC) announced on October 22, 2025 that Executive Chairman Peter Choo purchased an additional 105,824 shares in open-market trades, raising his personal holding to 187,500 shares (2.50%).

He also holds shares through related entities — Glorious Finance Limited (55% owner) and sole ownership of EP Capital Inc — which together represent 2,282,422 shares (19.45%). In aggregate he controls 2,388,246 shares, or 21.95% of outstanding shares. The company said it will update on any further purchases and advised investors to exercise caution when trading until further announcements.

CytoMed (NASDAQ: GDTC) submitted a cash bid on Oct 14, 2025 to acquire relevant assets of TC BioPharm Limited (TCBL) from joint administrators Michael Magnay and Rob Croxen, who were appointed on Oct 2, 2025. TCBL has completed a Phase I trial; CytoMed is conducting the Phase I ANGELICA trial in Singapore under an IND evaluating proprietary CAR T cells. The Proposed Acquisition aims to deepen CytoMed’s expertise in donor-derived gamma delta T cells, accelerate commercialization, and leverage Southeast Asia cost structures. Funding is planned from internal resources. More details, including transaction terms, will be announced when available; investors are advised to exercise caution.

CytoMed Therapeutics (NASDAQ:GDTC) announced the publication of a preclinical study conducted in collaboration with MD Anderson Cancer Center, focusing on donor-derived γδ T cells for treating acute myeloid leukemia (AML). The research demonstrates promising potential for CytoMed's allogeneic γδ T cell therapy (CTM-GDT).

The study supports the company's advancement of γδ T cell-based treatments, following their leading product CAR-γδ T cells (CTM-N2D) which is currently in Phase 1 clinical trials in Singapore. CytoMed plans to expand clinical trials across Southeast Asia to provide novel immunotherapy options for patients with limited treatment alternatives.

CytoMed Therapeutics (NASDAQ: GDTC) has announced significant developments following its October 2024 acquisition of a Malaysian cord blood bank. The company has successfully expanded clinical-scale NK cells from decade-old cryopreserved cord blood units and is reorganizing its structure through LongevityBank, which owns the licensed cord blood bank IPSC Depository.

The company is pursuing a dual-strategy approach: CytoMed will focus on donor blood-derived allogeneic therapies (currently in Phase I and Phase II trials), while LongevityBank will concentrate on autologous therapies. Management and EP Capital Inc plan to invest up to $500,000 in LongevityBank's equity at double the acquisition valuation. The company intends to eventually spinoff LongevityBank as a standalone cord blood-based biopharmaceutical company.

CytoMed Therapeutics (NASDAQ: GDTC), a Singapore-based clinical stage biopharmaceutical company, has announced an At-the-Market (ATM) offering program to raise up to $4.3 million through R.F. Lafferty & Co. as sales agent.

The company will determine the timing and amount of share sales based on market conditions and capital needs. Proceeds will support general corporate purposes, business development initiatives, capital expenditures, and potential strategic acquisitions. Additionally, CytoMed reported that its recently acquired cord blood bank has attracted 2,500 new customers since its acquisition in August 2024, contributing to 2025 revenue.

CytoMed Therapeutics (NASDAQ: GDTC) has successfully completed dose level 1 of its ANGELICA Trial, a Phase I dose-escalation clinical study evaluating CTM-N2D in late-stage cancer patients. The company plans to proceed with dose level 2 in Q3 2025.

The trial focuses on CTM-N2D, an innovative allogeneic NKG2DL-targeting CAR gamma delta T cell therapy designed to treat advanced solid tumors and blood cancers. Unlike traditional CAR-T therapies, CTM-N2D uses donor-derived cells that don't require patient matching, potentially offering a more accessible treatment option. The therapy targets NKG2DL, proteins commonly found in various cancers, providing a potentially broader application compared to conventional treatments.

CytoMed Therapeutics (NASDAQ: GDTC) reported its full-year 2024 financial results, showing improved performance with a reduced net loss of $1.85 million, a 39% improvement from 2023's $3.03 million loss. The company's topline income reached $624,771 in 2024, up from $588,423 in 2023.

Key financial highlights:

• Cash balance: $3.64 million as of December 31, 2024
• Research expenses: $1.40 million, up from $1.16 million in 2023
• Employee benefits: $453,321, increased from $332,413 in 2023

Notable clinical developments include the launch of the ANGELICA Trial, a first-in-human CAR T trial using donor-derived allogeneic gamma delta T cells. The company expanded operations by acquiring a licensed cord blood bank in Malaysia and is preparing for clinical trials in India. CytoMed plans to establish a New York liaison office and expects sufficient cash runway through 2026, while exploring potential funding opportunities for growth and acquisitions.

CytoMed Therapeutics (NASDAQ: GDTC) released a chairman's letter highlighting key achievements in 2024 and outlining plans for 2025. The company, based in Singapore and Malaysia, specializes in producing affordable GMP-grade immune cells for cancer and autoimmune disease treatment.

Key 2024 accomplishments include: becoming a clinical-stage biopharma with the initiation of the ANGELICA trial, the first-in-human CAR T trial using donor-derived allogeneic gamma delta T cells; acquiring a licensed cord blood bank for US$450,000; establishing strategic collaborations in China and India; advancing iPSC-derived hybrid immune cell development; and participating in an AI project for infectious diseases treatment.

For 2025, CytoMed plans to: release initial ANGELICA trial results by mid-year; submit a US FDA IND for their allogeneic gamma delta T cells; establish presence in New York; and implement revenue-generating methods through compassionate use programs. The company reports having over one year of cash runway from their US$10 million NASDAQ IPO.